Gaurav Gupta to Assume EVP and Chief Information & Digital Officer Role at Merck

Merck has appointed Gaurav Gupta as Executive Vice President and Chief Information & Digital Officer (CIDO). He joined the company this week and will officially assume the role on September 1, succeeding Dave Williams, who is preparing to retire after leading the company's digital transformation initiatives.

In his new position, Gaurav will oversee Merck's global information technology, digital transformation, data, and artificial intelligence strategy, supporting the company's mission to advance healthcare innovation.

Building on a Strong Digital Foundation

Sharing the announcement on LinkedIn, Gaurav expressed his appreciation for Dave Williams' leadership and the thoughtful transition process leading up to his retirement.

He acknowledged Dave's contributions in establishing Merck as a digital leader within the life sciences industry and noted that he looks forward to building on this foundation while advancing the company's technology priorities.

Accelerating AI, Data, and Digital Innovation

As EVP and Chief Information & Digital Officer, Gaurav will lead initiatives focused on expanding the use of artificial intelligence, enterprise data, and digital technologies to accelerate innovation across Merck's global operations.

His leadership will play a key role in supporting the company's efforts to enhance research, business operations, and patient outcomes through technology-driven transformation.

Looking Ahead

Gaurav's appointment reflects Merck's continued investment in digital leadership as AI and advanced technologies become increasingly central to innovation across the pharmaceutical and healthcare sectors.

With responsibility for the company's information and digital strategy, he will help shape the next phase of Merck's technology roadmap while supporting its purpose of improving and saving lives worldwide.

About Merck

Merck is a global healthcare company focused on developing innovative medicines, vaccines, biologic therapies, and animal health products. Through continued investment in research, science, and digital innovation, the company works to improve health outcomes and address some of the world's most pressing medical challenges.